Omni-PAGE?預制膠(Hepes-Tris)
Omni-PAGE?Hepes-Tris Gels
本產品常溫運輸;4℃可保存18個月。切勿置于0℃以下,以免凝膠發生凍裂。
產品組分
產(chan)品特點(dian)
go
o穩定性高——采用自動化灌膠生產技術,確保了產品質量(liang)的(de)高穩定(ding)性和重復性;
go
o晰——采用玻璃膠板,有效(xiao)減少蛋(dan)白非特異性吸附,使蛋(dan)白條帶更為尖銳,清晰;
go
o電泳快速——電泳(yong)時間短,在(zai)150V電壓下(xia),電泳40~50min即可完成(cheng);
go
o操作簡便——膠夾(jia)(jia)打(da)開(kai)極為輕松(song),只需用刀片(pian)在膠夾(jia)(jia)一側輕輕劃一下即可打(da)開(kai);
go
o通用性強——凝膠中(zhong)不含SDS,可(ke)用于變性(xing)和非變性(xing)電泳(需使用非變性(xing)電泳液);
go
o兼容性強——兼容市場(chang)上主流的mini電(dian)泳(yong)槽,如(ru)Bio-Rad,Invitrogen,天(tian)能和(he)君意東(dong)方等;
go
o種類多樣——提供多種濃度的均(jun)一(yi)(yi)膠(jiao)(jiao)和梯(ti)度膠(jiao)(jiao)。均(jun)一(yi)(yi)膠(jiao)(jiao)可(ke)選濃度:8%,10%,12%,15%。梯度膠可選濃度:4~15%,4~20%,8~20%。
產品(pin)簡介
goodOmni-PAGE?預(yu)制膠(Hepes-Tris)是一款安全、快捷、高性能(neng)的(de)預制聚丙烯(xi)酰(xian)胺(an)凝膠(jiao),常用于PAGE和Western Blot檢測(ce)。本(ben)預制膠(jiao)含有1.5cm高度的4%濃縮膠。丙(bing)烯酰胺與甲叉雙丙(bing)烯酰胺的(de)比例(li)為29:1,凝膠厚度為1.5mm,加(jia)樣(yang)孔數為10孔/15孔,最(zui)大上樣量為60μL/30μL,膠板尺寸:寬(kuan)×高×厚度為(wei)98×84×4.1mm;凝膠尺寸(cun)為:寬×高×厚度為81 × 74×1.5mm。
1. Mei, J., Zhou, W. J., Zhu, X. Y., Lu, H., Wu, K., Yang, H. L., ... & Wang, J. (2018). Suppression of autophagy and HCK signaling promotes PTGS2high FCGR3? NK cell differentiation triggered by ectopic endometrial stromal cells. Autophagy, 14(8), 1376-1397. (IF 16.016)
good2. Ji, L., Qian, W., Gui, L., Ji, Z., Yin, P., Lin, G. N., ... & Gao, W. Q. (2020). Blockade of β-Catenin–Induced CCL28 Suppresses Gastric Cancer Progression via Inhibition of Treg Cell Infiltration. Cancer Research, 80(10), 2004-2016. (IF 12.701)
good3. LI, Jing, et al. Selenium Status in Diet Affects Acetaminophen-Induced Hepatotoxicity via Interruption of Redox Environment. Antioxidants & Redox Signaling, 2021, 34.17: 1355-1367.(IF 8.401)
good4. Li, J., Cheng, P., Li, S., Zhao, P., Han, B., Ren, X., ... & Lu, J. (2020). Selenium status in diet affects acetaminophen-induced hepatotoxicity via interruption of redox environment. Antioxidants and Redox Signaling, (ja). (IF 8.401)
good5. LIU, Suxian, et al. Uncovering the Mechanism of Curcuma in the Treatment of Ulcerative Colitis Based on Network Pharmacology, Molecular Docking Technology, and Experiment Verification. Evidence-Based Complementary and Alternative Medicine, 2021, 2021.(IF 2.629)